Catherine A. Lozupone | |
---|---|
Born | Catherine Anne Lozupone 1975 (age 49–50) |
Academic background | |
Alma mater | Villanova University Colorado State University University of Colorado Boulder |
Doctoral advisor | Rob Knight |
Academic work | |
Institutions | University of Colorado Denver |
Main interests | microbiologist |
Notable works | Diversity,Stability and Resilience of the Human Gut Microbiota |
Catherine Anne Lozupone (born 1975) is an American microbiologist who specializes in bacteria and how they impact human health. Her noted work in trying to determine what constitutes "normal" gut bacteria,led to her creation of the UniFrac algorithm,used by researchers to plot the relationships between microbial communities in the human body. Dr. Lozupone is currently at Anschutz Medical Campus School of Medicine as an Associate Professor. [1]
Catherine A. Lozupone earned a Bachelor of Science from Villanova University in 1997 and went on to obtain a master's degree from Colorado State University in Fort Collins,Colorado in 1999. [2] She went on to complete her doctoral work at the University of Colorado Boulder studying under Rob Knight,who is the founder of the American Gut Project. [3] At the time of her doctoral research,little was known about the microbiome (genes of the bacteria,archaea,microscopic eukaryotes,and viruses interacting in an environment) of the gut and the symbiotic relationship between host and bacteria. Her thesis delineated the UniFrac algorithm which has allowed researchers to visualize the relationships between microbial communities in the human gut,how they interact,and how they might be related to specific diseases. [4] Lozupone's work,detailed in a 2012 paper which appeared in Nature entitled "Diversity,Stability and Resilience of the Human Gut Microbiota",was noted for its attempt to analyze what is the "normal" bacterial state in the human gut. By approaching the gut as an ecosystem,scientists are then able to factor in the effects of lifestyle,diet,health status which might change the bacterial makeup present in the gastrointestinal tract. [3]
In 2013,after completing her post-doctoral research in Knight's lab,Lozupone started her own lab at the University of Colorado Denver, [3] where she works in the Department of Biomedical Informatics as an associate professor. She has begun evaluating the composition differences in the microbiome of healthy individuals versus those of HIV positive individuals. She is attempting to determine if T cell loss causes change in the bacteria levels,thus prompting chronic inflammation for people living with HIV. [5] According to Thomson Reuters,Lozupone was one of the most cited researchers in the world in 2014. [6]
{{cite book}}
: |journal=
ignored (help)CS1 maint: location missing publisher (link)The human microbiome is the aggregate of all microbiota that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the gastrointestinal tract, skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and the biliary tract. Types of human microbiota include bacteria, archaea, fungi, protists, and viruses. Though micro-animals can also live on the human body, they are typically excluded from this definition. In the context of genomics, the term human microbiome is sometimes used to refer to the collective genomes of resident microorganisms; however, the term human metagenome has the same meaning.
Bacillota is a phylum of bacteria, most of which have gram-positive cell wall structure. The renaming of phyla such as Firmicutes in 2021 remains controversial among microbiologists, many of whom continue to use the earlier names of long standing in the literature.
Gut microbiota, gut microbiome, or gut flora are the microorganisms, including bacteria, archaea, fungi, and viruses, that live in the digestive tracts of animals. The gastrointestinal metagenome is the aggregate of all the genomes of the gut microbiota. The gut is the main location of the human microbiome. The gut microbiota has broad impacts, including effects on colonization, resistance to pathogens, maintaining the intestinal epithelium, metabolizing dietary and pharmaceutical compounds, controlling immune function, and even behavior through the gut–brain axis.
Dysbiosis is characterized by a disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution. For example, a part of the human microbiota such as the skin flora, gut flora, or vaginal flora, can become deranged (unbalanced), when normally dominating species become underrepresented and species that normally are outcompeted or contained increase to fill the void. Similar to the human gut microbiome, diverse microbes colonize the plant rhizosphere, and dysbiosis in the rhizosphere, can negatively impact plant health. Dysbiosis is most commonly reported as a condition in the gastrointestinal tract or plant rhizosphere.
Skin flora, also called skin microbiota, refers to microbiota that reside on the skin, typically human skin.
Oral microbiology is the study of the microorganisms (microbiota) of the oral cavity and their interactions between oral microorganisms or with the host. The environment present in the human mouth is suited to the growth of characteristic microorganisms found there. It provides a source of water and nutrients, as well as a moderate temperature. Resident microbes of the mouth adhere to the teeth and gums to resist mechanical flushing from the mouth to stomach where acid-sensitive microbes are destroyed by hydrochloric acid.
The Human Microbiome Project (HMP) was a United States National Institutes of Health (NIH) research initiative to improve understanding of the microbiota involved in human health and disease. Launched in 2007, the first phase (HMP1) focused on identifying and characterizing human microbiota. The second phase, known as the Integrative Human Microbiome Project (iHMP) launched in 2014 with the aim of generating resources to characterize the microbiome and elucidating the roles of microbes in health and disease states. The program received $170 million in funding by the NIH Common Fund from 2007 to 2016.
Microbiota are the range of microorganisms that may be commensal, mutualistic, or pathogenic found in and on all multicellular organisms, including plants. Microbiota include bacteria, archaea, protists, fungi, and viruses, and have been found to be crucial for immunologic, hormonal, and metabolic homeostasis of their host.
Prevotella is a genus of Gram-negative bacteria.
Nancy A. Moran is an American evolutionary biologist and entomologist, University of Texas Leslie Surginer Endowed Professor, and co-founder of the Yale Microbial Diversity Institute. Since 2005, she has been a member of the United States National Academy of Sciences. Her seminal research has focused on the pea aphid, Acyrthosiphon pisum and its bacterial symbionts including Buchnera (bacterium). In 2013, she returned to the University of Texas at Austin, where she continues to conduct research on bacterial symbionts in aphids, bees, and other insect species. She has also expanded the scale of her research to bacterial evolution as a whole. She believes that a good understanding of genetic drift and random chance could prevent misunderstandings surrounding evolution. Her current research goal focuses on complexity in life-histories and symbiosis between hosts and microbes, including the microbiota of insects.
UniFrac, a shortened version of unique fraction metric, is a distance metric used for comparing biological communities. It differs from dissimilarity measures such as Bray-Curtis dissimilarity in that it incorporates information on the relative relatedness of community members by incorporating phylogenetic distances between observed organisms in the computation.
Microbiota-accessible carbohydrates (MACs) are carbohydrates that are resistant to digestion by a host's metabolism, and are made available for gut microbes, as prebiotics, to ferment or metabolize into beneficial compounds, such as short chain fatty acids. The term, ‘‘microbiota-accessible carbohydrate’’ contributes to a conceptual framework for investigating and discussing the amount of metabolic activity that a specific food or carbohydrate can contribute to a host's microbiota.
A microbiome is the community of microorganisms that can usually be found living together in any given habitat. It was defined more precisely in 1988 by Whipps et al. as "a characteristic microbial community occupying a reasonably well-defined habitat which has distinct physio-chemical properties. The term thus not only refers to the microorganisms involved but also encompasses their theatre of activity". In 2020, an international panel of experts published the outcome of their discussions on the definition of the microbiome. They proposed a definition of the microbiome based on a revival of the "compact, clear, and comprehensive description of the term" as originally provided by Whipps et al., but supplemented with two explanatory paragraphs, the first pronouncing the dynamic character of the microbiome, and the second clearly separating the term microbiota from the term microbiome.
Microbiomes of the built environment is a field of inquiry into the communities of microorganisms that live in human constructed environments like houses, cars and water pipes. It is also sometimes referred to as microbiology of the built environment.
Pharmacomicrobiomics, proposed by Prof. Marco Candela for the ERC-2009-StG project call, and publicly coined for the first time in 2010 by Rizkallah et al., is defined as the effect of microbiome variations on drug disposition, action, and toxicity. Pharmacomicrobiomics is concerned with the interaction between xenobiotics, or foreign compounds, and the gut microbiome. It is estimated that over 100 trillion prokaryotes representing more than 1000 species reside in the gut. Within the gut, microbes help modulate developmental, immunological and nutrition host functions. The aggregate genome of microbes extends the metabolic capabilities of humans, allowing them to capture nutrients from diverse sources. Namely, through the secretion of enzymes that assist in the metabolism of chemicals foreign to the body, modification of liver and intestinal enzymes, and modulation of the expression of human metabolic genes, microbes can significantly impact the ingestion of xenobiotics.
In the field of microbiome research, a group of species is said to show a phylosymbiotic signal if the degree of similarity between the species' microbiomes recapitulates to a significant extent their evolutionary history. In other words, a phylosymbiotic signal among a group of species is evident if their microbiome similarity dendrogram could prove to have significant similarities with their host's phylogenic tree. For the analysis of the phylosymbiotic signal to be reliable, environmental differences that could shape the host microbiome should be either eliminated or accounted for. One plausible mechanistic explanation for such phenomena could be, for example, a result of host immune genes that rapidly evolve in a continuous arms race with members of its microbiome.
The human milk microbiota, also known as human milk probiotics (HMP), encompasses the microbiota–the community of microorganisms–present within the human mammary glands and breast milk. Contrary to the traditional belief that human breast milk is sterile, advancements in both microbial culture and culture-independent methods have confirmed that human milk harbors diverse communities of bacteria. These communities are distinct in composition from other microbial populations found within the human body which constitute the human microbiome.
María Gloria Domínguez-Bello is a Venezuelan-American microbial ecologist that has worked on adaptations of gut fermentation organs in animals, gastric colonization by bacteria, assembly of the microbiota in early life, effect of practices that reduce microbiota transmission and colonization in humans, and effect of urbanization. She is the Henry Rutgers Professor of Microbiome and Health at Rutgers University, New Brunswick. Her lab at collaborates in multidisciplinary science, integrating microbiology, immunology, pediatrics, nutrition, anthropology, environmental engineering and architecture/urban studies, and microbial ecology.
Janet Knutson Jansson is an American biological scientist who is the Chief Scientist at the Pacific Northwest National Laboratory. She investigates complex microbial communities, including those found in soil and the human gut. Jansson is part of the Phenotypic Response of the Soil Microbiome to Environmental Perturbations Science Focus Area, and is a Fellow of the American Society for Microbiology.
{{cite book}}
: |journal=
ignored (help)CS1 maint: location missing publisher (link)